Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05154045 · ClinicalTrials.gov registry record · NA
Postprandial Glycemic Response in Adults With Type 2 Diabetes
A NA study, sponsored by Abbott Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT05154045: Completed NA study, sponsored by Abbott Nutrition.
NCT05154045 is a NA study that has completed, run by Abbott Nutrition. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05154045, a NA study, has completed, sponsored by Abbott Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a randomized, controlled, crossover study to compare the effects of two treatments on postprandial glucose in adults with type 2 diabetes.
Primary Outcome
Calculated from blood samples
Interventions
- OTHER Test Meal
- OTHER Experimental Formula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-04-09 |
| Est. Completion | 2022-07-12 |
| Phase | NA |
What the finished NCT05154045 record still lists
NCT05154045 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Test Meal is the first listed.
NCT05154045 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05154045 about?
NCT05154045 is a clinical study titled "Postprandial Glycemic Response in Adults With Type 2 Diabetes". This is a randomized, controlled, crossover study to compare the effects of two treatments on postprandial glucose in adults with type 2 diabetes.
What is the current status of trial NCT05154045?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2022-04-09. Estimated completion is 2022-07-12.
What interventions are being tested in trial NCT05154045?
The interventions under investigation include: Test Meal (OTHER), Experimental Formula (OTHER).
Who is sponsoring clinical trial NCT05154045?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05154045's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI